Melissa E Murray

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1139008/publications.pdf

Version: 2024-02-01

231 papers	21,847 citations	11608 70 h-index	11030 137 g-index
265 all docs	265 docs citations	265 times ranked	18186 citing authors

#	Article	IF	Citations
1	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.5	2,805
2	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	3.9	1,060
3	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain, 2019, 142, 1503-1527.	3.7	873
4	Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurology, The, 2011, 10, 785-796.	4.9	733
5	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron, 2017, 95, 808-816.e9.	3.8	493
6	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
7	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	2.4	388
8	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	3.9	380
9	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurology, The, 2012, 11, 868-877.	4.9	355
10	TDP-43 is a key player in the clinical features associated with Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 811-824.	3.9	336
11	C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science, 2015, 348, 1151-1154.	6.0	332
12	Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nature Neuroscience, 2015, 18, 1175-1182.	7.1	330
13	Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Medicine, 2013, 14, 754-762.	0.8	326
14	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain, 2012, 135, 765-783.	3.7	322
15	MRI correlates of neurofibrillary tangle pathology at autopsy. Neurology, 2008, 71, 743-749.	1.5	312
16	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312.	0.4	310
17	Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau). Journal of Molecular Neuroscience, 2011, 45, 384-389.	1.1	295
18	Staging TDP-43 pathology in Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 441-450.	3.9	278

#	Article	IF	Citations
19	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathologica, 2011, 122, 673-690.	3.9	277
20	Clinicopathologic and¹¹C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimerâ€™s disease spectrum. Brain, 2015, 138, 1370-1381.	3.7	270
21	C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nature Neuroscience, 2016, 19, 668-677.	7.1	268
22	Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathologica, 2015, 130, 77-92.	3.9	267
23	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. NeuroImage: Clinical, 2016, 11, 802-812.	1.4	249
24	Updated TDP-43 in Alzheimerâ€™s disease staging scheme. Acta Neuropathologica, 2016, 131, 571-585.	3.9	244
25	Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurology, The, 2013, 12, 978-988.	4.9	232
26	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218
27	New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurology, The, 2021, 20, 222-234.	4.9	214
28	Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology, 2013, 81, 2032-2038.	1.5	191
29	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 2016, 7, 11253.	5.8	174
30	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurology, The, 2017, 16, 917-924.	4.9	159
31	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	1.5	158
32	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimer's Research and Therapy, 2014, 6, 1.	3.0	156
33	Multisite study of the relationships between antemortem [¹¹C]PIBâ€PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.4	155
34	AVâ€1451 tau and Î²â€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	2.8	152
35	Functional Impact of White Matter Hyperintensities in Cognitively Normal Elderly Subjects. Archives of Neurology, 2010, 67, 1379-85.	4.9	146
36	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.5	143

#	Article	IF	Citations
37	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathologica, 2014, 127, 397-406.	3.9	133
38	FUS is Phosphorylated by DNA-PK and Accumulates in the Cytoplasm after DNA Damage. Journal of Neuroscience, 2014, 34, 7802-7813.	1.7	129
39	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	3.9	125
40	APOE Îµ4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 2018, 91, e1182-e1195.	1.5	122
41	Selective loss of cortical endothelial tight junction proteins during Alzheimerâ€™s disease progression. Brain, 2019, 142, 1077-1092.	3.7	120
42	Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain, 2011, 134, 3264-3275.	3.7	119
43	Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathologica, 2014, 128, 411-421.	3.9	119
44	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. Journal of Neuroscience, 2014, 34, 16247-16255.	1.7	117
45	[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathologica, 2016, 132, 931-933.	3.9	116
46	Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimer's and Dementia, 2018, 14, 352-366.	0.4	116
47	Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. Alzheimer's and Dementia, 2021, 17, 1554-1574.	0.4	114
48	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	1.5	113
49	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.4	113
50	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. JAMA Neurology, 2017, 74, 718.	4.5	107
51	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica, 2015, 130, 863-876.	3.9	104
52	Neuropathologically defined subtypes of Alzheimerâ€™s disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathologica, 2012, 124, 681-692.	3.9	103
53	Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimerâ€™s disease. Brain, 2014, 137, 1533-1549.	3.7	100
54	APOE Îµ2 is associated with increased tau pathology in primary tauopathy. Nature Communications, 2018, 9, 4388.	5.8	100

#	Article	IF	Citations
55	Rapid eye movement sleep behavior disorder and subtypes in autopsyâ€confirmed dementia with Lewy bodies. Movement Disorders, 2012, 27, 72-78.	2.2	99
56	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. Alzheimer's and Dementia, 2018, 14, 563-575.	0.4	98
57	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
58	TAR DNAâ€binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. Annals of Neurology, 2015, 78, 697-709.	2.8	96
59	APOE4-mediated amyloid-Î² pathology depends on its neuronal receptor LRP1. Journal of Clinical Investigation, 2019, 129, 1272-1277.	3.9	96
60	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.4	93
61	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology, 2012, 79, 553-560.	1.5	91
62	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
63	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathologica, 2015, 130, 559-573.	3.9	89
64	Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathologica, 2013, 125, 289-302.	3.9	87
65	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. Autophagy, 2018, 14, 1404-1418.	4.3	87
66	C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology, 2013, 81, 1332-1341.	1.5	84
67	Interaction of tau with HNRNPA2B1 and N6-methyladenosine RNA mediates the progression of tauopathy. Molecular Cell, 2021, 81, 4209-4227.e12.	4.5	84
68	Progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a description of 55 cases and comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068.	1.5	81
69	Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathologica Communications, 2018, 6, 63.	2.4	79
70	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiology of Disease, 2019, 121, 327-337.	2.1	79
71	A Quantitative Postmortem MRI Design Sensitive to White Matter Hyperintensity Differences and Their Relationship With Underlying Pathology. Journal of Neuropathology and Experimental Neurology, 2012, 71, 1113-1122.	0.9	78
72	Increased cytoplasmic TDP-43 reduces global protein synthesis by interacting with RACK1 on polyribosomes. Human Molecular Genetics, 2017, 26, 1407-1418.	1.4	78

#	Article	IF	Citations
73	Frontotemporal dementia with the V337M MAPT mutation. Neurology, 2017, 88, 758-766.	1.5	76
74	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica, 2017, 134, 255-269.	3.9	76
75	The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 141, 631-650.	3.9	75
76	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	1.5	74
77	Mitochondrial ATP synthase activity is impaired by suppressedO-GlcNAcylation in Alzheimer's disease. Human Molecular Genetics, 2015, 24, 6492-6504.	1.4	74
78	Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 225-234.	3.9	73
79	Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to rapid eye movement (REM) sleep behaviour disorder. Neuropathology and Applied Neurobiology, 2012, 38, 142-152.	1.8	72
80	Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients. Brain Research, 2014, 1584, 15-21.	1.1	70
81	The limbic and neocortical contribution of Î±â€synuclein, tau, and amyloid Î² to disease duration in dementia with Lewy bodies. Alzheimer's and Dementia, 2018, 14, 330-339.	0.4	69
82	Sex and age interact to determine clinicopathologic differences in Alzheimerâ€™s disease. Acta Neuropathologica, 2018, 136, 873-885.	3.9	69
83	Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A. Acta Neuropathologica, 2015, 129, 53-64.	3.9	67
84	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	3.7	67
85	Frequency of LATE neuropathologic change across the spectrum of Alzheimerâ€™s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathologica, 2022, 144, 27-44.	3.9	67
86	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathologica, 2019, 137, 227-238.	3.9	65
87	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
88	Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Molecular Neurodegeneration, 2014, 9, 38.	4.4	63
89	Approach to atypical Alzheimerâ€™s disease and case studies of the major subtypes. CNS Spectrums, 2017, 22, 439-449.	0.7	63
90	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62

#	Article	IF	Citations
91	Association of Apolipoprotein E Îµ4 With Transactive Response DNA-Binding Protein 43. JAMA Neurology, 2018, 75, 1347.	4.5	60
92	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. Neurology, 2013, 81, 1681-1689.	1.5	58
93	Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. Molecular Neurodegeneration, 2015, 10, 46.	4.4	58
94	Disease specificity and pathologic progression of tau pathology in brainstem nuclei of Alzheimer's disease and progressive supranuclear palsy. Neuroscience Letters, 2011, 491, 122-126.	1.0	53
95	Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimerâ€™s disease presenting as logopenic progressive aphasia. Brain and Language, 2013, 127, 127-134.	0.8	53
96	Late-onset Alzheimer disease genetic variants in posterior cortical atrophy and posterior AD. Neurology, 2014, 82, 1455-1462.	1.5	51
97	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiology of Aging, 2019, 77, 26-36.	1.5	51
98	Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease. JAMA Neurology, 2020, 77, 225.	4.5	50
99	Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci. Acta Neuropathologica, 2016, 132, 197-211.	3.9	49
100	Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDPâ€•17) due to microtubuleâ€•associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy. Neuropathology and Applied Neurobiology, 2017, 43, 200-214.	1.8	49
101	Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia. Neurobiology of Aging, 2014, 35, 1769-1777.	1.5	48
102	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.4	48
103	Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy. Acta Neuropathologica, 2018, 136, 709-727.	3.9	47
104	Subtypes of dementia with Lewy bodies are associated with Î±-synuclein and tau distribution. Neurology, 2020, 95, e155-e165.	1.5	47
105	LRRK2 exonic variants and risk of multiple system atrophy. Neurology, 2014, 83, 2256-2261.	1.5	46
106	Antemortem MRI findings associated with microinfarcts at autopsy. Neurology, 2014, 82, 1951-1958.	1.5	45
107	Protein contributions to brain atrophy acceleration in Alzheimerâ€™s disease and primary age-related tauopathy. Brain, 2020, 143, 3463-3476.	3.7	45
108	Plasma sphingolipid changes with autopsyâ€•confirmed Lewy body or Alzheimer's pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 43-50.	1.2	44

#	Article	IF	Citations
109	Loss of TMEM106B leads to myelination deficits: implications for frontotemporal dementia treatment strategies. Brain, 2020, 143, 1905-1919.	3.7	44
110	Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimerâ€™s disease. Nature Communications, 2021, 12, 2311.	5.8	44
111	Early discrimination reversal learning impairment and preserved spatial learning in a longitudinal study of Tg2576 APPsw mice. Neurobiology of Aging, 2007, 28, 1248-1257.	1.5	43
112	Linkage of frontotemporal dementia to chromosome 17: clinical and neuropathological characterization of phenotype. American Journal of Human Genetics, 1996, 59, 1306-12.	2.6	42
113	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.4	41
114	Corticobasal degeneration with olivopontocerebellar atrophy and TDP-43 pathology: an unusual clinicopathologic variant of CBD. Acta Neuropathologica, 2013, 125, 741-752.	3.9	40
115	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	2.4	40
116	Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. JAMA Neurology, 2019, 76, 710.	4.5	39
117	A novel tau mutation, p.K317N, causes globular glial tauopathy. Acta Neuropathologica, 2015, 130, 199-214.	3.9	38
118	Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG). Journal of Neuropathology and Experimental Neurology, 2017, 76, 605-619.	0.9	38
119	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. Brain, 2013, 136, 455-470.	3.7	37
120	Diffuse Lewy body disease manifesting as corticobasal syndrome. Neurology, 2018, 91, e268-e279.	1.5	37
121	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
122	APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	5.8	37
123	Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimerâ€™s disease?. Alzheimer's Research and Therapy, 2014, 6, 24.	3.0	35
124	Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. Alzheimer's and Dementia, 2019, 15, 1218-1228.	0.4	34
125	Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 1372-1383.	0.4	34
126	Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology. Alzheimer's and Dementia, 2021, 17, 417-430.	0.4	34

#	Article	IF	Citations
127	The Longitudinal Earlyâ€onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimer's and Dementia, 2021, 17, 2043-2055.	0.4	34
128	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.4	32
129	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	2.2	32
130	Sensitivityâ€“Specificity of Tau and Amyloid Î² Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022.	2.8	32
131	A computational model of neurodegeneration in Alzheimerâ€™s disease. Nature Communications, 2022, 13, 1643.	5.8	32
132	Similarities between familial and sporadic autopsy-proven progressive supranuclear palsy. Neurology, 2013, 80, 2076-2078.	1.5	31
133	Role for the microtubule-associated protein tau variant p.A152T in risk of Î±-synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.5	31
134	Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72. Acta Neuropathologica, 2013, 126, 545-554.	3.9	30
135	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
136	An Increase in Aβ42 in the Prefrontal Cortex is Associated with a Reversal-Learning Impairment in Alzheimers Disease Model Tg2576 APPsw Mice. Current Alzheimer Research, 2008, 5, 385-391.	0.7	29
137	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	1.5	29
138	Ethnoracial differences in Alzheimer's disease from the FLorida Autopsied Multiâ€Ethnic (FLAME) cohort. Alzheimer's and Dementia, 2019, 15, 635-643.	0.4	29
139	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.5	27
140	Progressive Supranuclear Palsy: High-Field-Strength MR Microscopy in the Human Substantia Nigra and Globus Pallidus. Radiology, 2013, 266, 280-288.	3.6	26
141	Transmission of Soluble and Insoluble Î±-Synuclein to Mice. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1158-1169.	0.9	25
142	A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration. Acta Neuropathologica, 2015, 130, 145-157.	3.9	24
143	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology, 2018, 90, e940-e946.	1.5	24
144	MAPT haplotype diversity in multiple system atrophy. Parkinsonism and Related Disorders, 2016, 30, 40-45.	1.1	23

#	Article	IF	Citations
145	Evaluating pathogenic dementia variants in posterior cortical atrophy. Neurobiology of Aging, 2016, 37, 38-44.	1.5	23
146	TDP-43 in Alzheimerâ€™s disease is not associated with clinical FTLD or Parkinsonism. Journal of Neurology, 2014, 261, 1344-1348.	1.8	22
147	Daytime sleepiness in dementia with Lewy bodies is associated with neuronal depletion of the nucleus basalis of Meynert. Parkinsonism and Related Disorders, 2018, 50, 99-103.	1.1	22
148	Tau Subtypes of Alzheimerâ€™s Disease Determined in vivo Using Flortaucipir PET Imaging. Journal of Alzheimer's Disease, 2019, 71, 1037-1048.	1.2	22
149	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108.	1.5	21
150	Loss of Tmem106b is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity. Acta Neuropathologica Communications, 2018, 6, 42.	2.4	20
151	TDP-43 and Alzheimerâ€™s Disease Pathologic Subtype in Non-Amnestic Alzheimerâ€™s Disease Dementia. Journal of Alzheimer's Disease, 2018, 64, 1227-1233.	1.2	20
152	Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations. Annals of Clinical and Translational Neurology, 2019, 6, 1782-1796.	1.7	20
153	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	1.2	19
154	Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathologica, 2022, 143, 33-53.	3.9	19
155	Confirmation of ¹²³I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. Journal of Nuclear Medicine, 2020, 61, 1628-1635.	2.8	18
156	Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 5-14.	1.2	17
157	Tremor in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 27, 93-97.	1.1	17
158	Parkinson's disease susceptibility variants and severity of Lewy body pathology. Parkinsonism and Related Disorders, 2017, 44, 79-84.	1.1	17
159	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	1.5	17
160	Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases. Brain, 2021, 144, 1082-1088.	3.7	17
161	Pickâ€™s disease: clinicopathologic characterization of 21 cases. Journal of Neurology, 2020, 267, 2697-2704.	1.8	17
162	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	0.9	16

#	Article	IF	Citations
163	Understanding Biomarkers of Neurodegeneration: Novel approaches to detecting tau pathology. Nature Medicine, 2015, 21, 219-220.	15.2	15
164	Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease. Movement Disorders, 2017, 32, 1584-1593.	2.2	15
165	Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurology, 2018, 75, 212.	4.5	15
166	Association of MAPT H1 subhaplotypes with neuropathology of lewy body disease. Movement Disorders, 2019, 34, 1325-1332.	2.2	15
167	Non-random distribution among a guild of parasitoids: implications for community structure and host survival. Ecological Entomology, 2006, 31, 557-563.	1.1	14
168	Transmission of Soluble and Insoluble Î±-Synuclein to Mice. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1158-1169.	0.9	14
169	Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. Movement Disorders, 2019, 34, 1655-1662.	2.2	14
170	Brain atrophy in primary ageâ€related tauopathy is linked to transactive response DNAâ€binding protein of 43 kDa. Alzheimer's and Dementia, 2019, 15, 799-806.	0.4	14
171	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimerâ€™s Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	1.2	14
172	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	2.4	14
173	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. Acta Neuropathologica, 2022, 144, 159-160.	3.9	14
174	Association between transactive response DNA-binding protein ofÂ43 kDa type and cognitive resilience to Alzheimerâ€™s disease: aÂcase-control study. Neurobiology of Aging, 2020, 92, 92-97.	1.5	13
175	Alzheimerâ€™s disease and progressive supranuclear palsy share similar transcriptomic changes in distinct brain regions. Journal of Clinical Investigation, 2022, 132, .	3.9	13
176	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	0.9	12
177	FTDPâ€17 with Pick bodyâ€like inclusions associated with a novel tau mutation, p.E372G. Brain Pathology, 2017, 27, 612-626.	2.1	11
178	Clinicopathological and ¹²³Iâ€<scp>FP</scp>â€<scp>CIT SPECT</scp> correlations in patients with dementia. Annals of Clinical and Translational Neurology, 2018, 5, 376-381.	1.7	11
179	Reply: LATE to the PART-y. Brain, 2019, 142, e48-e48.	3.7	11
180	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. Neurobiology of Aging, 2021, 99, 11-18.	1.5	11

#	Article	IF	Citations
181	Neuropathologic scales of cerebrovascular disease associated with diffusion changes on MRI. Acta Neuropathologica, 2022, 144, 1117-1125.	3.9	11
182	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.5	10
183	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. Journal of Neuro-Oncology, 2018, 136, 373-378.	1.4	9
184	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. Neurology, 2020, 95, e35-e45.	1.5	9
185	Genome-wide analysis identifies a novel LINC-PINT splice variant associated with vascular amyloid pathology in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 93.	2.4	9
186	Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. Acta Neuropathologica Communications, 2020, 8, 172.	2.4	8
187	MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features. Acta Neuropathologica Communications, 2020, 8, 218.	2.4	8
188	Loss of Tmem106b leads to cerebellum Purkinje cell death and motor deficits. Brain Pathology, 2021, 31, e12945.	2.1	8
189	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	1.2	8
190	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
191	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. Journal of Alzheimer's Disease, 2021, 80, 683-693.	1.2	7
192	Amyloid PET scan. Neurology, 2017, 89, 2029-2030.	1.5	6
193	Evaluation of Associations of Alzheimerâ€™s Disease Risk Variants that Are Highly Expressed in Microglia with Neuropathological Outcome Measures. Journal of Alzheimer's Disease, 2019, 70, 659-666.	1.2	6
194	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations. Brain, 2022, 145, 2472-2485.	3.7	6
195	Development of the continuously variable volume reactor for flow injection analysis. Analytica Chimica Acta, 2002, 455, 287-304.	2.6	5
196	Latent trait modeling of tau neuropathology in progressive supranuclear palsy. Acta Neuropathologica, 2021, 141, 667-680.	3.9	5
197	Regional patterns of atrophy on MRI in Alzheimerâ€™s disease: Neuropsychological features and progression rates in the ADNI cohort. Advances in Alzheimer's Disease, 2013, 02, 135-147.	0.3	5
198	Imaging tau pathology in Alzheimerâ€™s disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies. Molecular Neurodegeneration, 2022, 17, .	4.4	5

#	Article	IF	Citations
199	A proteomic study identifies different levels of light chain ferritin in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathologica, 2011, 122, 727-736.	3.9	4
200	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4
201	In vivo imaging and autoradiography in a case of autopsy-confirmed Pick disease. Neurology: Clinical Practice, 2021, 11, 10.1212/CPJ.0000000000000755.	0.8	4
202	The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida. American Journal of Neurodegenerative Disease, 2016, 5, 94-101.	0.1	4
203	Intraneuronal amyloid-Î² accumulation in basal forebrain cholinergic neurons: a marker of vulnerability, yet inversely related to neurodegeneration. Brain, 2015, 138, 1444-1445.	3.7	3
204	An MRIâ€Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. Journal of Neuroimaging, 2016, 26, 264-268.	1.0	3
205	Case Studies Illustrating Focal Alzheimerâ€™s, Fluent Aphasia, Late-Onset Memory Loss, and Rapid Dementia. Neurologic Clinics, 2016, 34, 699-716.	0.8	3
206	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. NeuroImage: Clinical, 2022, 34, 102954.	1.4	3
207	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 143, 571-583.	3.9	3
208	Brain tau deposition linked to systemic causes of death in normal elderly. Neurobiology of Aging, 2017, 50, 163-166.	1.5	2
209	O4â€04â€01: Differentiating clinicopathologic and genetic aspects of hippocampal sclerosis in Alzheimer's disease from limbic predominant Alzheimer's disease and â€œpureâ€•hippocampal sclerosis. Alzheimer's and Dementia, 2012, 8, P620.	0.4	1
210	O1-12-03: THAL AMYLOID PHASE: CLINICOPATHOLOGIC AND PIB-PET IMPLICATIONS OF AD PATHOPHYSIOLOGY. , 2014, 10, P153-P155.		1
211	TDP-43 AMPLIFIES MEMORY LOSS AND HIPPOCAMPAL ATROPHY IN ALZHEIMER'S DISEASE. , 2014, 10, P279-P280.		1
212	F3-02-01: The relationship of primary age-related tauopathy (PART) to snap: Controversy or parallel?. , 2015, 11, P212-P213.		1
213	O3â€04â€04: Alzheimer's Disease May Not be More Common in Women; Men May be More Commonly Misdiagnosed. Alzheimer's and Dementia, 2016, 12, P292.	0.4	1
214	Relationships between lewy and tau pathologies in 375 consecutive nonâ€Alzheimer's olfactory bulbs. Movement Disorders, 2018, 33, 333-334.	2.2	1
215	The neuropathology of dementia.. , 2018, , 41-66.		1
216	Quantitative characterization of brain Î²-amyloid using a joint PiB/FDG PET image histogram. , 2014, , .		0

#	Article	IF	Citations
217	O1-01-01: PATHOLOGIC INVESTIGATION OF MICROINFARCTS AND ASSOCIATION WITH GRAY MATTER ATROPHY ON ANTEMORTEM MRI. , 2014, 10, P128-P128.		0
218	IC-P-066: PATHOLOGIC INVESTIGATION OF MICROINFARCTS AND ASSOCIATION WITH GRAY MATTER ATROPHY ON ANTEMORTEM MRI. , 2014, 10, P36-P37.		0
219	IC-02-04: EARLY, BUT NOT ADVANCED, NEUROFIBRILLARY TANGLE PATHOLOGY OR AMYLOID-B PATHOLOGY SIGNIFICANTLY ASSOCIATES WITH ABNORMAL HIPPOCAMPAL SIZE IN COGNITIVELY NORMAL ELDERLY. , 2014, 10, P5-P5.		0
220	O3-04-01: NEXT-GENERATION RNA SEQUENCING IN ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY. , 2014, 10, P214-P215.		0
221	P1-202: HISTORY OF HEAD INJURY AND ALZHEIMER'S DISEASE (AD) NEUROPATHOLOGY. , 2014, 10, P377-P377.		0
222	Neuroimaging in Dementias. , 2015, , 107-118.		0
223	ICâ€01â€05: Neuropathologic Features of AV1451 TAU Pet Autoradiography in Dementia. Alzheimer's and Dementia, 2016, 12, P4.	0.4	0
224	Quantitative characterization of brain Î²-amyloid in 718 normal subjects using a joint PiB/FDG PET image histogram. , 2016, , .		0
225	[S3â€“01â€“03]: ATYPICAL ALZHEIMER's DISEASE PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P877.	0.4	0
226	F1â€01â€01: NEUROPATHOLOGIC HETEROGENEITY OF ALZHEIMER'S DISEASE AND RELATED DISORDERS. Alzheimer's and Dementia, 2018, 14, P199.	0.4	0
227	Mild cognitive impairment associated with eventual Lewy body disease pathology: Clinical characterization of 75 patients. Journal of the Neurological Sciences, 2019, 405, 20.	0.3	0
228	Neuroimaging in dementias. , 2020, , 187-197.		0
229	Neuropathologicallyâ€defined subtypes of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e039957.	0.4	0
230	Neuropathologic underpinnings of PET and fluid biomarker measures. Alzheimer's and Dementia, 2021, 17, .	0.4	0
231	Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures. Acta Neuropathologica Communications, 2022, 10, .	2.4	0